• Protease Inhibitor Cocktail for Lysosome Research

  2026-08-28

  Lysosomal repair is an increasingly important translational question, but mechanistic conclusions can be weakened when proteolysis begins immediately after lysis. This article connects TECPR1-mediated membrane tubulation with practical sample-preservation strategy, showing how an EDTA-free broad-spectrum cocktail can support phosphorylation-sensitive assays, protein-complex analysis, and reproducible validation without being confused with an in-cell lysosome-repair intervention.

• DiscoveryProbe Metabolism-related Compound Library Guide

  2026-08-27

  A scenario-based guide to improving cell viability, proliferation, and cytotoxicity workflows with the DiscoveryProbe™ Metabolism-related Compound Library, SKU L1032. It explains practical controls, dilution logic, mechanistic interpretation, and vendor-selection criteria using product specifications and peer-reviewed metabolic signaling evidence.

• Proliferation Tracing Models Tumor Relapse

  2026-08-27

  The reference study introduces a dual recombinase proliferation-tracing and ablation system in spontaneous MMTV-PyMT breast tumors. By selectively removing recently proliferating cells and profiling the residual disease with single-cell RNA sequencing, the model reveals cellular and microenvironmental features associated with relapse and provides a platform for testing therapies against low-cycling tumor reservoirs.

• Sisomicin Workflows for Infection Research

  2026-08-26

  Build more informative Sisomicin assays by pairing extracellular susceptibility testing with intracellular infection models and exposure-aware analysis. This workflow helps distinguish ribosome-targeted antibacterial activity from failures caused by resistance, cell penetration, recovery bias, or compound handling.

• Astrocytic GAT-3 Links GABA to Dentate Gyrus Memory

  2026-08-26

  This study identifies astrocytic GAT-3 as an active signaling element in the entorhinal cortex–dentate gyrus circuit, linking GABA uptake to astrocytic Ca2+ elevations and enhanced excitatory transmission. Its electrophysiological, optogenetic, imaging, and behavioral evidence further connects this pathway to GluN2B-containing NMDA receptors and contextual fear-memory formation.

• Gap19: A Cx43 Assay Decision Framework

  2026-08-25

  Gap19 is a selective connexin 43 hemichannel blocker for separating Cx43 hemichannel signaling from gap junction communication. This guide translates macrophage NF-κB evidence and neuroprotection data into practical assay choices for astrocyte, inflammation, and ischemia research.

• HHV-7 DNA in Ocular Toxoplasmosis: Study Analysis

  2026-08-25

  This case report describes the concurrent detection of Toxoplasma gondii and human herpesvirus 7 DNA in vitreous humor from a patient with recurrent, treatment-refractory ocular toxoplasmosis. Its main contribution is compartment-specific molecular evidence suggesting that HHV-7 reactivation may complicate chronic infectious uveitis, while also demonstrating why PCR findings must be interpreted alongside clinical response and treatment history.

• BRCA2, PARP1 Retention, and RAD51 Filament Protection

  2026-08-24

  The 2025 Nature study identifies a direct mechanism linking PARP inhibitor-induced PARP1 retention to instability of RAD51 filaments at resected DNA. Its biochemical, single-molecule, and cellular data show that full-length BRCA2 prevents PARP1 from occupying DNA and thereby protects homologous recombination, clarifying why BRCA2-deficient cells are particularly vulnerable to PARP inhibition.

• HHV-7 DNA in Ocular Toxoplasmosis: Study Insights

  2026-08-23

  Miyase et al. identified human herpesvirus 7 DNA alongside Toxoplasma gondii DNA in vitreous humor from a patient with recurrent, treatment-refractory ocular toxoplasmosis. The case highlights how compartment-specific multiplex PCR and repeat sampling can reveal a possible viral cofactor in chronic infectious uveitis, while also underscoring the limits of causal inference from a single patient.

• THZ1: Covalent CDK7 Inhibitor Workflow

  2026-08-22

  THZ1 combines nanomolar CDK7 potency with irreversible covalent target engagement, making it valuable for linking transcriptional disruption to proliferation and apoptosis. This practical guide adapts the compound for T-ALL research, cancer biology, and exploratory studies of enhancer-dependent transcription.

• Triacetin: From Adipocyte Assays to Mechanism

  2026-08-21

  Triacetin, also called glyceryl triacetate, is more than a formulation excipient: it can influence lipid metabolism, adipogenesis, and tumor-cell phenotypes. This evidence-focused guide explains how to distinguish direct bioactivity from solvent or vehicle effects when designing biochemical and cell-based assays.

• PX-478 in Prenatal Hypoxia–Related ASD Models

  2026-08-21

  The reference study shows that pharmacological HIF-1α inhibition with PX-478 reduced autism-like behaviors and hippocampal neuronal necrosis in rat offspring exposed to prenatal hypoxia. Its staged postnatal design links behavioral outcomes with HIF-1α, PTEN, VEGF, and toxicity measurements, while also highlighting the importance of treatment timing.

• Dual-Action Inhibitors Reprogram p38α Dephosphorylation

  2026-08-20

  A bioRxiv preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can also reshape the activation loop to accelerate its dephosphorylation by WIP1. The structural and biochemical findings introduce a mechanism for improving kinase-inhibitor potency and specificity, while highlighting the need for cellular validation before translation.

• Topotecan: Topoisomerase I Inhibition and Clinical Evidence

  2026-08-20

  The reference review presents topotecan as a water-soluble camptothecin derivative that stabilizes the DNA–topoisomerase I cleavable complex, linking a distinctive mechanism to apoptosis and cytotoxicity. Its pharmacokinetic properties, hematologic toxicity, activity in ovarian and small-cell lung cancers, and potential for combination therapy remain the central practical lessons for cancer research.

• Verapamil in Hypoxia-Driven Urothelial Inflammation

  2026-08-19

  Verapamil ((±)-Verapamil) is more than a cardiovascular reference compound. Evidence from an enzyme-induced hypoxia model positions it as a practical perturbation tool for studying duration-dependent ROS/TXNIP/NLRP3 signaling in urothelial cells, while its calcium-channel and P-glycoprotein pharmacology demands disciplined controls. This article translates those findings into a reproducible experimental and translational strategy.

444 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page